Target and Biomarker Research
De-risking & accelerating drug discovery with
precision target and biomarker identification, assessment & validation
Context
Bridging the Gap: The Role of Target and Biomarker Research in Biopharma Innovation
Biopharma wins come from hard-fought battles. There are about 7000+ diseases with known molecular basis but less than a 1000 have FDA approved treatments. Translation of lab findings to approved drugs continues to be highly risky and costly. The key bottleneck is in incomplete understanding of human disease biology.
Advancements in genomics, proteomics, transcriptomics, and organoids research enable de-risking with better target identification and patient stratification. However, the expertise needed to distill molecular data into insights remains in short supply.
Aganitha’s Disease Biomarker and Target Insights Platform & Services (DBTIPS™) triage & integrate signals from multi-omics, real-world evidence & market intelligence to enable effective target & biomarker identification, assessment & validation.
Key Solution Areas
Solution area
Disease Research
Aganitha DBTIPSTM, DISTILLTM & NGS DataWorksTM provide comprehensive solutions for disease research, accelerating R&D journeys from available genomic evidence, multi-omics studies, past clinical trials, real-world data (RWD), published literature and knowledge bases, to translatable understanding of molecular and biological processes underlying diseases.
Solution area
Target and Biomarker Research
Aganitha DBTIPSTM auto-collates and analyses evidence, market intelligence and target properties to enable comprehensive target and biomarker identification, assessment & validation.
